Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers

Journal of the National Cancer Institute

Volumn 100, Issue 6, 2008, Pages 407-420

  Gillison, Maura L ^a,d   D'Souza, Gypsyamber ^b   Westra, William ^c   Sugar, Elizabeth ^a   Xiao, Weihong ^a   Begum, Shahnaz ^c   Viscidi, Raphael ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIS; CAPSID PROTEIN; VIRUS ANTIBODY; VIRUS DNA;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRINKING BEHAVIOR; FEMALE; HEAD AND NECK CARCINOMA; HIGH RISK BEHAVIOR; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MOUTH HYGIENE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEOTIDE SEQUENCE; ORAL SEXUAL CONTACT; PRIORITY JOURNAL; RISK FACTOR; SEXUAL BEHAVIOR; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TOOTH DISEASE; VIRUS INFECTION; AGED; ALPHAPAPILLOMAVIRUS; BLOOD; CANNABIS SMOKING; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; HEAD AND NECK TUMOR; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; RISK; RISK ASSESSMENT; SMOKING; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ALCOHOL DRINKING; ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA, VIRAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; ODDS RATIO; ORAL HYGIENE; RISK ASSESSMENT; RISK FACTORS; SEXUAL BEHAVIOR; SMOKING; VIRAL LOAD;

EID: 41449085148     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn025     Document Type: Article

References (50)

1. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31(6):744-754.
2. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg. 2001;125(1):1-9.
3. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709-720.
4. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24(5):736-747.
5. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006;24(36):5630-5636.
6. Fakhry C, Westra WH, Sigui L, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261-269.
7. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996;56(11):2488-2492.
8. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer. 2003;107(3):394-400.
9. Slebos RJ, Yi Y, Ely K, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12(3 pt 1):701-709.
10. Ragin CC, Taioli E, Weissfeld JL, et al. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer. 2006;95(10):1432-1438.
11. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332(11):712.
12. Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst. 2004;96(13):998-1006.
13. Smeets SJ, Braakhuis BJ, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 2006;25(17):2558- 2564.
14. Dahlgren L, Mellin H, Wangsa D, et al. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer. 2003;107(2):244-249.
15. Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer. 2007;43(2):415-432.
16. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944-1956.
17. Huang CC, Qiu JT, Kashima ML, Kurman RJ, Wu TC. Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. Mod Pathol. 1998;11(10):971-977.
18. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357-361.
19. D'Souza G, Sugar E, Ruby W, Gravitt P, Gillison M. Analysis of the effect of DNA purification on detection of human papillomavirus in oral rinse samples by PCR. J Clin Microbiol. 2005;43(11):5526-5535.
20. Kreimer AR, Alberg AJ, Viscidi R, Gillison ML. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis. 2004;31(4):247-256.
21. Benhamou S, Benhamou E, Flamant R. Lung cancer risk associated with cigar and pipe smoking. Int J Cancer. 1986;37(6):825-829.
22. Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1829-1834.
23. Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst. 1998;90(21):1626-1636.
24. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95(23):1772-1783.
25. Smith EM, Ritchie JM, Summersgill KF, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst. 2004;96(6):449-455.
26. State-specific prevalence of current cigarette smoking among adults and secondhand smoke rules and policies in homes and workplaces - United States, 2005. MMWR Morb Mortal Wkly Rep. 2006;55(42):1148-1151.
27. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis. 2002;186(10):1396-1402.
28. Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF. Epidemiologic review of marijuana use and cancer risk. Alcohol. 2005;35(3):265-275.
29. Sidney S, Quesenberry CP Jr, Friedman GD, Tekawa IS. Marijuana use and cancer incidence (California, United States). Cancer Causes Control. 1997;8(5):722-728.
30. Rosenblatt KA, Daling JR, Chen C, Sherman KJ, Schwartz SM. Marijuana use and risk of oral squamous cell carcinoma. Cancer Res. 2004;64(11):4049-4054.
31. Llewellyn CD, Johnson NW, Warnakulasuriya KA. Risk factors for oral cancer in newly diagnosed patients aged 45 years and younger: a case-control study in Southern England. J Oral Pathol Med. 2004;33(9):525-532.
32. Zhang ZF, Morgenstern H, Spitz MR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 1999;8(12):1071-1078.
33. Turner CF, Ku L, Rogers SM, Lindberg LD, Pleck JH, Sonenstein FL. Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science. 1998;280(5365):867-873.
34. Kettenes-van den Bosch JJ, Salemink CA, Cannabis XVI. Constituents of marihuana smoke condensate. J Chromatogr. 1977;131 : 422-424.
35. Barsky SH, Roth MD, Kleerup EC, Simmons M, Tashkin DP. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst. 1998;90(16):1198-1205.
36. Darling MR, Learmonth GM, Arendorf TM. Oral cytology in cannabis smokers. SADJ. 2002;57(4):132-135.
37. Berglund BA, Boring DL, Howlett AC. Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. Adv Exp Med Biol. 1999;469:527-533.
38. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5(5):400-411.
39. Klein TW, Newton C, Larsen K, et al. The cannabinoid system and immune modulation. J Leukoc Biol. 2003;74(4):486-496.
40. Cabral GA, Dove Pettit DA. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol. 1998;83(1-2):116-123.
41. Zhu LX, Sharma S, Stolina M, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 2000;165(1):373-380.
42. McKallip RJ, Nagarkatti M, Nagarkatti PS. Delt a-9- tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 2005;174(6):3281-3289.
43. Roth MD, Baldwin GC, Tashkin DP. Effects of delt a-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids. 2002;121(1-2):229-239.
44. Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med. 1997;156(5):1606-1613.
45. Pacifici R, Zuccaro P, Farre M, et al. Combined immunomodulating properties of 3,4-methylenedioxymethamphetamine (MDMA) and cannabis in humans. Addiction. 2007;102(6):931-936.
46. Lunn CA, Reich EP, Bober L. Targeting the CB2 receptor for immune modulation. Expert Opin Ther Targets. 2006;10(5):653-663.
47. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-475.
48. Crook T, Morgenstern JP, Crawford L, Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. 1989;8(2):513-519.
49. Tonetti MS. Cigarette smoking and periodontal diseases: etiology and management of disease. Ann Periodontol. 1998;3(1):88-101.
50. Tezal M, Grossi SG, Ho AW, Genco RJ. Alcohol consumption and periodontal disease. The Third National Health and Nutrition Examination Survey. J Clin Periodontol. 2004;31(7):484-488.